<--- Back to Details
First PageDocument Content
Medicine / Clinical medicine / Health / Healthcare-associated infections / Drug rehabilitation / Morphinans / Opioid antagonists / Buprenorphine/naloxone / Sublingual administration / Addiction / Hepatitis / Opiate
Date: 2014-10-23 17:25:28
Medicine
Clinical medicine
Health
Healthcare-associated infections
Drug rehabilitation
Morphinans
Opioid antagonists
Buprenorphine/naloxone
Sublingual administration
Addiction
Hepatitis
Opiate

ECFH Chart Note Patient Name Date of Birth Date

Add to Reading List

Source URL: echo.unm.edu

Download Document from Source Website

File Size: 15,52 KB

Share Document on Facebook

Similar Documents

Acute Hepatitis C in the PROUD pilot study Juan Tiraboschi, Liz Brodnicki, Brady Michael, John Saunders, Schembri Gabriel, Mark Roche, Julie Fox on behalf of the PROUD study

DocID: 1vngt - View Document

PRESS RELEASE AbbVie Receives Health Canada Approval of HOLKIRATM PAK for the Treatment of Chronic Genotype 1 Hepatitis C  New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for geno

DocID: 1vlwz - View Document

PRESS RELEASE AbbVie’s MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes   

DocID: 1vjI2 - View Document

APASL and CEVHAP Partnership: a Hepatitis-Free World November

DocID: 1vgwC - View Document

California Institute of Technology Hepatitis B Vaccination Offer Form Occupational Exposure to Bloodborne Pathogens Please complete this form if you may come in contact with human blood or other potentially infectious hu

DocID: 1vf93 - View Document